The Quality Overall Summary (QOS) is an element of a drug marketing application that provides a substantially condensed summary of the quality-related data provided in the submission. Regulators can use the QOS to more effectively assess applications and more rapidly comprehend the quality information in the context of patient risk, including the proposed control strategy and any other planned steps to mitigate that risk. Patients benefit from the greater assessment efficiency by having improved access to drugs that are designed and manufactured to consistently and safely fulfill claims in the label.
Artigos recentes
- Quality documentation for medicinal products when used with a medical device- effective from 1/01/2022
- Artificial intelligence in medicine regulation
- Clinical Trial Information System (CTIS) – Sponsor Handbook
- Sistema europeu de ensaios clínicos lançado em janeiro
- EMA new guidelines on veterinary pharmacovigilance
- Veterinary product information templates
- MDCG 2021-19 Guidance note integration of the UDI within an organisation’s quality management system
- The FDA finalized its guidance on the form and content requirements for unique device identifiers (UDI)